Spain reports first known human-to-human mpox clade 1b transmission outside Africa
December 11, 2025
The reported case of mpox clade 1b transmission in Spain without any travel link marks a critical warning for global public health. This case suggests that highly transmissible mpox strains can establish local human-to-human spread beyond endemic regions, even among vaccinated individuals. While vaccination remains essential for reducing severity, it is not a standalone safeguard against transmission. The finding underscores the need for vigilant surveillance, routine clade-specific testing, and rapid public health response in non-endemic countries. Mpox is no longer a distant threat. Preparedness, targeted vaccination, and community engagement must remain priorities even after emergency declarations are lifted.
The identification of a locally acquired mpox clade 1b infection in Spain represents a pivotal moment in the evolving global mpox landscape. For the first time, sustained human-to-human transmission of this clade appears to have occurred outside Africa without any direct travel link. This case challenges assumptions that clade 1b spread would remain confined to endemic regions or be limited to imported cases.
The patient, a vaccinated adult with no travel history, presented with mild but characteristic symptoms and was diagnosed through clade-specific PCR testing. That diagnosis highlights both progress and vulnerability. Surveillance systems were capable of detecting the infection, yet the case also demonstrates that vaccination does not fully prevent infection or transmission, particularly with more transmissible clades. Vaccines remain vital for reducing severe disease and complications, but they must be paired with robust public health measures.
This case also illustrates the limits of relying on emergency declarations as indicators of risk. Although the World Health Organization lifted the Public Health Emergency of International Concern after a decline in cases, viral evolution and changing transmission dynamics continue. Clade 1b has already shown its capacity for sustained spread in multiple African countries. Its appearance in Europe without travel exposure signals a real possibility of wider community transmission if vigilance lapses.
The authors’ recommendations are sound and urgent. Clade-specific testing should become standard for all confirmed cases. Targeted vaccination strategies, particularly for populations at higher risk of exposure, must be maintained. Just as important is coordination with community organizations to ensure rapid risk communication without stigma.
Mpox control now requires a long-term mindset. Surveillance, vaccination, and preparedness cannot be reactive or temporary. This case from Spain is not an anomaly to dismiss. It is an early signal that global health systems must remain alert, coordinated, and proactive in the face of an adaptable virus.